Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study.
Laham RJ, Chronos NA, Pike M, Leimbach ME, Udelson JE, Pearlman JD, Pettigrew RI, Whitehouse MJ, Yoshizawa C, Simons M. Laham RJ, et al. Among authors: yoshizawa c. J Am Coll Cardiol. 2000 Dec;36(7):2132-9. doi: 10.1016/s0735-1097(00)00988-8. J Am Coll Cardiol. 2000. PMID: 11127452 Free article. Clinical Trial.
Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease.
Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M. Udelson JE, et al. Among authors: yoshizawa c. Circulation. 2000 Oct 3;102(14):1605-10. doi: 10.1161/01.cir.102.14.1605. Circulation. 2000. PMID: 11015335 Clinical Trial.
A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells.
de Boer AW, Markowitz N, Lane HC, Saravolatz LD, Koletar SL, Donabedian H, Yoshizawa C, Duliege AM, Fyfe G, Mitsuyasu RT. de Boer AW, et al. Among authors: yoshizawa c. Clin Immunol. 2003 Mar;106(3):188-96. doi: 10.1016/s1521-6616(02)00038-4. Clin Immunol. 2003. PMID: 12706405 Clinical Trial.
Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial.
Conchillo M, de Knegt RJ, Payeras M, Quiroga J, Sangro B, Herrero JI, Castilla-Cortazar I, Frystyk J, Flyvbjerg A, Yoshizawa C, Jansen PL, Scharschmidt B, Prieto J. Conchillo M, et al. Among authors: yoshizawa c. J Hepatol. 2005 Oct;43(4):630-6. doi: 10.1016/j.jhep.2005.03.025. J Hepatol. 2005. PMID: 16024131 Clinical Trial.
Novel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells.
Gohara Y, Tomonobu N, Kinoshita R, Futami J, Audebert L, Chen Y, Komalasari NLGY, Jiang F, Yoshizawa C, Murata H, Yamamoto KI, Watanabe M, Kumon H, Sakaguchi M. Gohara Y, et al. Among authors: yoshizawa c. J Mol Med (Berl). 2023 Apr;101(4):431-447. doi: 10.1007/s00109-023-02292-w. Epub 2023 Mar 4. J Mol Med (Berl). 2023. PMID: 36869893 Free PMC article.
73 results